KPTI vs VRTX · rev $68.5M vs P/E 30, rev $3.33B
Karyopharm Therapeutics Inc (KPTI) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
KPTI currently screens at market cap $205.6M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the KPTI and VRTX stock pages for the full models.
Not investment advice.